Volume 29, Issue 2 (Monthly_May 2018)
Studies in Medical Sciences 2018, 29(2): 110-118 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moghtaran Bonab N, Hosseinpour feizi M A, Bonyadi M, Dastranj tabrizi A. GADD45A, A POTENTIAL MOLECULAR MARKER IN SEROUS EPITHELIAL OVARIAN CANCER. Studies in Medical Sciences 2018; 29 (2) :110-118
URL: http://umj.umsu.ac.ir/article-1-4235-en.html
URL: http://umj.umsu.ac.ir/article-1-4235-en.html
Tabriz University, Tabriz, Iran
Abstract: (4284 Views)
Background & Aims: ovarian cancer is the 4th leading cause of cancer-related death in women. In order to reduce its mortality and morbidity, identification and evaluation of specific diagnostic biomarkers are necessary. Given the importance of the GADD45A role in cell survival and death, its expression changes were investigated in benign, borderline and malignant ovarian serous tumors in the present work.
Materials & Methods: Fresh specimens from different types of ovarian serous tissues including 75 tumors and 20 normal gathered from patients who referred to Urmia Kosar and Tabriz Alzahra hospitals between 2015 and 2017 and stored in -80°C. After making a diagnosis by a pathologist, RNA extraction was performed with TRIzol kit, cDNA was synthesized by Takara kit and then the GADD45A gene expression was evaluated by Real-Time PCR
Results: The analysis revealed that GADD45A gene expression level showed a significant difference between malignant and normal tissue (p<0.0001). In addition, we found a significant reduction trend in expression of the GADD45A gene from benign to borderline to malignant tumors.
Conclusion: Based on our findings, it has been shown that the GADD45A gene expression level significantly reduced in cancer samples. Therefore, this gene expression level may be used to identify the disease stage in ovarian serous tumors. In addition, its expression level can be considered as a target in cancer therapy.
Materials & Methods: Fresh specimens from different types of ovarian serous tissues including 75 tumors and 20 normal gathered from patients who referred to Urmia Kosar and Tabriz Alzahra hospitals between 2015 and 2017 and stored in -80°C. After making a diagnosis by a pathologist, RNA extraction was performed with TRIzol kit, cDNA was synthesized by Takara kit and then the GADD45A gene expression was evaluated by Real-Time PCR
Results: The analysis revealed that GADD45A gene expression level showed a significant difference between malignant and normal tissue (p<0.0001). In addition, we found a significant reduction trend in expression of the GADD45A gene from benign to borderline to malignant tumors.
Conclusion: Based on our findings, it has been shown that the GADD45A gene expression level significantly reduced in cancer samples. Therefore, this gene expression level may be used to identify the disease stage in ovarian serous tumors. In addition, its expression level can be considered as a target in cancer therapy.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
